AmKor Enters Into Licensing Agreement With Hengdian For Neu2000
AmKor Pharma (AmKor) and Hengdian Group (Hengdian) have entered into a licensing agreement for further development and commercialisation of Neu2000 in China. As per the terms of the
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).